The 81% prescriber implementation rate: what it means

Understanding why not all medication recommendations become prescriber actions and how to interpret pharmacy review effectiveness

Published 3 April 2026

Introduction

Medication reviews generate recommendations for prescriber action: deprescribe this agent, reduce this dose, switch to alternative medication, monitor for specific concern. Yet not all recommendations translate into prescriber actions. Research from pharmacy review programmes indicates prescriber implementation rates of 70 to 85 percent, with average rates around 81 percent. This means approximately 1 in 5 medication review recommendations are not implemented by prescribers.

For insurers investing in medication review programmes, understanding why implementation rates are not 100 percent is essential. Non-implementation represents either pharmacist misjudgement (recommendation was not clinically appropriate) or prescriber non-compliance (recommendation was appropriate but prescriber chose not to implement). Understanding this distinction helps insurers interpret review value and decide when additional prescriber engagement is warranted.

What the 81% Rate Means

Definition of Implementation

Implementation is measured as: recommendation made, prescriber document reviewed, prescriber change implemented (medication dose reduced, agent ceased, or switched). Implementation does not require documentation of full adherence (some claimants may not fill prescriptions for deprescribed agents). Implementation means the prescriber has taken the recommended action.

Non-implementation means: recommendation made, prescriber aware of recommendation, prescriber has not taken recommended action at 3-month or 6-month follow-up assessment.

Statistical Interpretation

For a medication review generating 10 recommendations, expectation is approximately 8 to 9 will be implemented by prescriber. For a review with 20 recommendations, expectation is 16 to 17 implementations. The 81% rate is relatively stable across medication classes, review types, and prescriber types (GPs and specialists both average approximately 80 to 82% implementation).

Reasons for Non-Implementation

Legitimate Clinical Disagreement (50-60% of non-implementations)

Prescribers may disagree with recommendation based on clinical judgement not visible to reviewing pharmacist. Examples: patient may have trial of medication ongoing that needs more time to demonstrate efficacy; prescriber may know of alternative indication for medication not documented in insurance file; prescriber may have specific clinical concerns about recommendation (hypotension risk, interaction concern) that override recommendation. This represents legitimate clinical difference of opinion.

Claimant Non-Compliance (15-20% of non-implementations)

Prescriber may agree with recommendation but claimant refuses implementation. Claimant may attribute medication to injury recovery and refuse deprescribing despite pharmacist and prescriber agreement. Claimant may have concerns about symptom rebound if medication ceased. In these cases, prescriber cannot ethically override claimant autonomy, so recommendation goes unimplemented.

Communication Failure (10-15% of non-implementations)

Recommendation may not have been effectively communicated to prescriber, or prescriber may not have understood recommendation. Poorly formatted recommendations, recommendations sent to incorrect contact address, or recommendations lost in administrative process create communication gaps leading to non-implementation without clinical disagreement.

Prescriber Oversight (5-10% of non-implementations)

Prescriber may simply have forgotten to implement recommendation, particularly if recommendation requires specific action (contacting pharmacy, completing paperwork). This represents administrative non-compliance rather than clinical disagreement.

Factors Associated with Higher Implementation Rates

Recommendation Clarity and Specificity

Recommendations phrased as clear directives ("Deprescribe sertraline over 4-week period" or "Reduce amlodipine from 10mg to 5mg daily") are implemented at higher rates (85-90%) than vague recommendations ("Consider reducing blood pressure medication" or "Review antidepressant efficacy"). Specificity increases implementation by approximately 5-10 percentage points.

Evidence-Based Reasoning

Recommendations grounded in clear clinical or cost evidence are implemented at higher rates (85-88%) than recommendations based on preference or convention. Recommendations with evidence cited (e.g., "Evidence does not support opioid therapy beyond 90 days, recommend deprescribing plan") achieve higher compliance than recommendations based on clinical impression.

Prescriber-Pharmacist Relationship

Prescribers who have established relationships with reviewing pharmacists and trust their recommendations implement at higher rates (85-90%) than prescribers receiving first-time recommendations from unknown sources. Building prescriber relationships increases implementation rates significantly.

Insurer-Prescriber Alignment

When insurers communicate directly with prescribers regarding medication review recommendations and insurer support for implementation, prescriber uptake increases substantially (85-92%). Prescribers are more likely to implement when they understand insurer supports the recommendation and will approve funding for alternative agents if necessary.

Factors Associated with Lower Implementation Rates

Prescriber Habit and Inertia

Some prescribers have established prescribing patterns (e.g., "all my hypertensive patients get this combination") and are resistant to change even when recommendations are evidence-based. Habit-driven prescribing achieves implementation rates of 60-70%, significantly lower than evidence-driven prescribing.

Specialist vs. Generalist Practice

Specialists achieve lower implementation rates (75-78%) than GPs for recommendations outside specialist domain. A cardiologist may resist de-escalation of cardiovascular medications even when pharmacist recommends reduction. Specialists view recommendations as potentially overriding their specialty expertise.

Recommendations Affecting High-Cost Patient Relationships

Prescribers may be reluctant to implement recommendations that reduce medication utilisation if high medication usage has been associated with positive patient relationships or perceived clinical benefit. Deprescribing recommendations for medications perceived as beneficial may achieve lower implementation (70-75%) due to prescriber perception that medication is helping despite objective evidence of limited benefit.

Recommendations Regarding Psychiatric Medications

Implementation rates for psychiatric medication recommendations average 75-80%, lower than medical medication recommendations. Prescribers may perceive psychiatric medication adjustments as more risky (psychotic episode relapse, suicide risk) and resist recommendations despite evidence supporting deprescribing.

Actionability of Non-Implemented Recommendations

When Non-Implementation Signals Recommendation Error

If multiple prescribers independently reject same recommendation across different claimants, this suggests pharmacist recommendation may be flawed. Review process quality control should flag recommendations with consistently low implementation across prescriber population, indicating recommendation framework may need adjustment.

When Non-Implementation Signals Prescriber Resistance

If specific prescriber consistently implements 50-60% of recommendations while other prescribers achieve 85-90% implementation, this suggests prescriber-specific resistance or disagreement. Insurer may benefit from targeted prescriber engagement with this specific clinician regarding recommendations rationale.

When Non-Implementation is Legitimate

Some non-implementation reflects legitimate clinical disagreement or patient autonomy. Insurers should not interpret all non-implementation as pharmacist failure or prescriber non-compliance. Approximately 15-25% of non-implementation is legitimate clinical disagreement that should not be overridden.

Optimising Implementation Rates

Enhanced Prescriber Engagement

Direct communication from insurer or claim manager to prescriber regarding medication review recommendations increases implementation by 5-10 percentage points. Prescribers are more likely to implement when recommendation is accompanied by explicit insurer support and communication from claim team.

Prescriber Education and Dialogue

When reviewing pharmacist offers to discuss recommendations directly with prescriber (versus one-way recommendation letter), implementation increases by 10-15 percentage points. Dialogue allows prescriber to voice concerns and allows pharmacist to adjust recommendation if legitimate clinical concerns are identified.

Incentive Alignment

When prescriber understands that recommendation implementation will benefit claimant outcome and reduce claim cost burden, implementation improves. Framing recommendations as cost-saving and outcome-improving increases prescriber motivation to implement.

Interpreting Implementation Rate in Claim Context

Expected Value of 81% Implementation

For a medication review with 20 recommendations, expect approximately 16 to be implemented. These 16 implementations represent significant medication changes: estimated 10-15% reduction in medication costs, 5-10% improvement in medication regimen quality, and 10-15% improvement in functional outcome trajectory in most cases.

Cost-Benefit Analysis with 81% Implementation

Medication review cost (typically AUD 800-1,200) for claim that generates 20 recommendations with 81% implementation rate and average cost-saving per recommendation of AUD 500-1,000 per year yields return on investment of 6-15 times medication review cost within 12 months. Even with only 81% implementation, medication review ROI is typically 4-10 times within 12 months.

Conclusion

The 81% prescriber implementation rate reflects a reasonable balance between evidence-based recommendations that are usually accepted and legitimate clinical scenarios where prescribers appropriately differ from reviewing pharmacist. Insurers should expect implementation rates in the 75-85% range from quality medication review programmes and view this as evidence of appropriate recommendation generation rather than failure. Non-implementation should be analysed to distinguish between legitimate clinical disagreement (acceptable) and true prescriber non-compliance or communication failure (targetable for improvement).